Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03570892 · ClinicalTrials.gov registry record · Phase 3
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
NCT03570892 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 330 participants.
The verdict
NCT03570892, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
Study Summary
This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.
Interventions
- DRUG Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
- DRUG Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2019-05-09 |
| Est. Completion | 2026-02-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03570892
The ClinicalTrials.gov registry entry for NCT03570892 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy is the first listed.
NCT03570892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03570892 about?
NCT03570892 is a clinical study titled "Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma". This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.
What is the current status of trial NCT03570892?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2019-05-09. Estimated completion is 2026-02-03.
What interventions are being tested in trial NCT03570892?
The interventions under investigation include: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy (DRUG), Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT) (DRUG).
Who is sponsoring clinical trial NCT03570892?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.